sBAFF mutants induce neutralizing antibodies against BAFF

被引:17
作者
Gao, Huiguang
Bian, Aina
Zheng, Yingru
Li, Rongfen
Ji, Qing
Huang, Gang
Hu, Daqiang
Zhang, Li
Gong, Wei
Hu, Ying
He, Fengtian [1 ]
机构
[1] Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing 400038, Peoples R China
[2] 404th Hosp PLA, Dept Clin Lab, Weihai 264200, Peoples R China
来源
FEBS LETTERS | 2007年 / 581卷 / 04期
基金
中国国家自然科学基金;
关键词
B cell activating factor belonging to the TNF family; autoimmune disorder; immunization;
D O I
10.1016/j.febslet.2006.12.060
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
B cell activating factor belonging to the TNF family (BAFF) is a novel member of the tumor necrosis factor (TNF) ligand family and plays an important role in B lymphocyte maturation and survival. Overexpression of BAFF is closely involved in the pathogenesis and progression of many kinds of autoimmune disorders; therefore, BAFF has been considered as an ideal therapeutic target for these conditions. In this study, we generated several candidate immune inhibitors of human BAFF by conjugating foreign immunodominant T-helper cell (Th) epitopes to the N- or C-terminus of five BAFF mutants. The recombined proteins were successfully expressed in Escherichia coli (E. coli) and purified by Ni-NTA chromatography. BALB/c mice immunized with the recombinant proteins produced high levels of anti-BAFF antibodies, and their sera inhibited the lymphocyte proliferationinducing activity of recombinant soluble BAFF and natural soluble BAFF. Moreover, antibodies cross-reactive with BAFF were detected in sera from hu-SCID mice immunized with the recombinant proteins. These results indicated that the recombinant BAFF mutants modified with Th epitopes could induce neutralizing antibodies against BAFF in vivo. This study may provide a valuable strategy for treating BAFF-associated autoimmune diseases. (c) 2007 Federation of European Biochemical Societies. Published by ElseAer B.V. All rights reserved.
引用
收藏
页码:581 / 586
页数:6
相关论文
共 27 条
[1]   Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator [J].
Baker, KP ;
Edwards, BM ;
Main, SH ;
Choi, GH ;
Wager, RE ;
Halpern, WG ;
Lappin, PB ;
Riccobene, T ;
Abramian, D ;
Sekut, L ;
Sturm, B ;
Poortman, C ;
Minter, RR ;
Dobson, CL ;
Williams, E ;
Carmen, S ;
Smith, R ;
Roschke, V ;
Hilbert, DM ;
Vaughan, TJ ;
Albert, VR .
ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3253-3265
[2]   A SEVERE COMBINED IMMUNODEFICIENCY MUTATION IN THE MOUSE [J].
BOSMA, GC ;
CUSTER, RP ;
BOSMA, MJ .
NATURE, 1983, 301 (5900) :527-530
[3]   THE SCID MOUSE MUTANT - DEFINITION, CHARACTERIZATION, AND POTENTIAL USES [J].
BOSMA, MJ ;
CARROLL, AM .
ANNUAL REVIEW OF IMMUNOLOGY, 1991, 9 :323-350
[4]   Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment - Relationships with B cell depletion, circulating antibodies, and clinical relapse [J].
Cambridge, G ;
Stohl, W ;
Leandro, MJ ;
Migone, TS ;
Hilbert, DM ;
Edwards, JCW .
ARTHRITIS AND RHEUMATISM, 2006, 54 (03) :723-732
[5]  
Cheema GS, 2001, ARTHRITIS RHEUM-US, V44, P1313, DOI 10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO
[6]  
2-S
[7]   Therapeutic antibodies elicited by immunization against TNF-α [J].
Dalum, I ;
Butler, DM ;
Jensen, MR ;
Hindersson, P ;
Steinaa, L ;
Waterston, AM ;
Grell, SN ;
Feldmann, M ;
Elsner, HI ;
Mouritsen, S .
NATURE BIOTECHNOLOGY, 1999, 17 (07) :666-669
[8]   Autoimmunity and tumor immunity induced by immune responses to mutations in self [J].
Engelhorn, ME ;
Guevara-Patiño, JA ;
Noffz, G ;
Hooper, AT ;
Lou, O ;
Gold, JS ;
Kappel, BJ ;
Houghton, AN .
NATURE MEDICINE, 2006, 12 (02) :198-206
[9]   Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome [J].
Groom, J ;
Kalled, SL ;
Cutler, AH ;
Olson, C ;
Woodcock, SA ;
Schneider, P ;
Tschopp, J ;
Cachero, TG ;
Batten, M ;
Wheway, J ;
Mauri, D ;
Cavill, D ;
Gordon, TP ;
Mackay, CR ;
Mackay, F .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (01) :59-68
[10]   Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators [J].
Hsu, BL ;
Harless, SM ;
Lindsley, RC ;
Hilbert, DM ;
Cancro, MP .
JOURNAL OF IMMUNOLOGY, 2002, 168 (12) :5993-5996